Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2024

This “Acute On Chronic Liver Failure - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Acute On Chronic Liver Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute On Chronic Liver Failure Understanding

Acute On Chronic Liver Failure: Overview

Acute-on-chronic liver failure (ACLF) is a syndrome characterised by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%-50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF. Using a liver-adapted sequential organ assessment failure score, it is possible to triage and prognosticate the outcome of patients with ACLF. The course of ACLF is dynamic and changes over the course of hospital admission.

Acute On Chronic Liver Failure - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute On Chronic Liver Failure pipeline landscape is provided which includes the disease overview and Acute On Chronic Liver Failure treatment guidelines. The assessment part of the report embraces, in depth Acute On Chronic Liver Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute On Chronic Liver Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute On Chronic Liver Failure R&D. The therapies under development are focused on novel approaches to treat/improve Acute On Chronic Liver Failure.

Acute On Chronic Liver Failure Emerging Drugs Chapters

This segment of the Acute On Chronic Liver Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute On Chronic Liver Failure Emerging Drugs

Hepa Stem: Promethera BiosciencesHepaStem® is Promethera®’s lead cell therapy product currently in Phase II clinical trials for Acute-on-Chronic Liver Failure. It consists of human allogeneic liver-derived medicinal signaling cells that are obtained from healthy, ethically donated organs and expanded in the manufacturing GMP factory. HepaStem® is administered as a simple peripheral intravenous infusion, after which it is transported via the bloodstream to the liver, where it is expected to act as a cargo and activate multiple key pathogenetic pathways. Preclinical and clinical findings suggest that HepaStem® enhances the liver’s own repair and regeneration processes by reducing inflammation as well as fibrogenesis thanks to its ability to inhibit hepatic stellate cell activation and collagen secretion, and even to degrade excessive extracellularmatrix.

TAK-242: Akaza Bioscience Akaza Bioscience is a biopharmaceutical company pioneering the development of Resatorvid (TAK-242), a novel immunological therapy for the treatment of Acute-on-Chronic Liver Failure (ACLF). Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. This pan-European study aims to investigate the safety and efficacy of TAK-242, as measured by changes in key biomarkers and 28-day survival rates. The trial will be a randomised, double-blind, placebo-controlled study in patients with Grade 1 or 2ACLF.

Acute On Chronic Liver Failure: Therapeutic Assessment

This segment of the report provides insights about the different Acute On Chronic Liver Failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute On Chronic Liver Failure

There are approx. 8+ key companies which are developing the therapies for Acute On Chronic Liver Failure. The companies which have their Acute On Chronic Liver Failure drug candidates in the most advanced stage, i.e. phase II include, Promethera Biosciences.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute On Chronic Liver Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute On Chronic Liver Failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute On Chronic Liver Failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute On Chronic Liver Failure drugs.

Acute On Chronic Liver Failure Report Insights

• Acute On Chronic Liver Failure Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute On Chronic Liver Failure Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute On Chronic Liver Failure drugs?
• How many Acute On Chronic Liver Failure drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute On Chronic Liver Failure?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute On Chronic Liver Failure therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute On Chronic Liver Failure and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Promethera Biosciences
• Akaza Bioscience
• RHEACELL
• Tianjin Weikai Bioeng., Ltd.
• Steminent Biotherapeutics Inc.
• Martin Pharmaceuticals, Inc.
• GNI Group Ltd.
• Versantis
• GENFIT

Key Products

• HepaStem
• TAK-242
• APZ 2
• Stemchymal
• LIVANTRA
• F573
• VS-01